Business Description
Celyad Oncology SA
ISIN : BE0974260896
Total Employee Number:
4Compare
Compare
Traded in other countries / regions
CYAD.BelgiumCLYYF.USA1C0.Germany0QFK.UK IPO Date
2014-01-06Description
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.06 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.34 | |||||
Debt-to-EBITDA | 0.76 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -113.45 | |||||
Beneish M-Score | 10.62 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 69.5 | |||||
3-Year FCF Growth Rate | 50.6 | |||||
3-Year Book Growth Rate | -34.4 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 0.13 | |||||
9-Day RSI | 3.94 | |||||
14-Day RSI | 14.76 | |||||
3-1 Month Momentum % | -28.57 | |||||
6-1 Month Momentum % | 66.67 | |||||
12-1 Month Momentum % | -50 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.92 | |||||
Quick Ratio | 1.92 | |||||
Cash Ratio | 0.94 | |||||
Days Inventory | 15330 | |||||
Days Sales Outstanding | 932.78 | |||||
Days Payable | 40530.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -25.6 | |||||
Shareholder Yield % | -7.29 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.91 | |||||
Operating Margin % | -6400 | |||||
Net Margin % | 3952.38 | |||||
EBITDA Margin % | 5228.57 | |||||
FCF Margin % | -33425 | |||||
OCF Margin % | -33425 | |||||
ROE % | Neg. Equity | |||||
ROA % | 12.5 | |||||
ROIC % | -30.61 | |||||
3-Year ROIIC % | -300.39 | |||||
ROC (Joel Greenblatt) % | 59.61 | |||||
ROCE % | 23.24 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 14.44 | |||||
PB Ratio | 4.81 | |||||
Price-to-Tangible-Book | 5 | |||||
EV-to-EBIT | 11.11 | |||||
EV-to-EBITDA | 9.04 | |||||
EV-to-Revenue | 472.86 | |||||
EV-to-FCF | -1.44 | |||||
Price-to-GF-Value | 1.67 | |||||
| Price-to-Net-Current-Asset-Value | 6.25 | |||||
Earnings Yield (Greenblatt) % | 9 | |||||
FCF Yield % | -59.29 |
Celyad Oncology SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Celyad Oncology SA Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2024 | 2024-08-02 | 0.25 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-08-02 | 0.25 (+0.00%) |
Show
Entries
Guru Commentaries on OTCPK:CLYYF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Celyad Oncology SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers